AKB-6899 |
Katalog-Nr.GC62277 |
Ro24-7429 ist ein potenter und oral aktiver HIV-1-Transaktivator-Protein-Tat-Antagonist. Ro24-7429 ist auch ein Runt-related Transcription Factor 1 (RUNX1)-Inhibitor. Ro24-7429 hat anti-HIV, antifibrotische und entzÜndungshemmende Wirkungen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1007377-55-0
Sample solution is provided at 25 µL, 10mM.
AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects[1].
AKB-6899 (10 μM; 24 hours) increases the leves of HIF-2α protein, with no corresponding increase in HIF-1α. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, with no effect on HIF-1α accumulation or VEGF production[1].
AKB-6899 (17.5 mg/kg; i.p.; 3 times per week; for 16 days) treatment significantly reduces tumor growth in a murine melanoma model[1].
[1]. Julie M Roda, et al. Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol. 2012 Sep 15;189(6):3168-77.
Average Rating: 5
(Based on Reviews and 23 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *